NCT03275402 - 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2018

Primary Completion Date

June 2, 2023

Study Completion Date

June 2, 2023

Conditions

NeuroblastomaCNS MetastasesLeptomeningeal Metastases

Interventions

BIOLOGICAL

131I-omburtamab

Murine IgG1 monoclonal antibody radiolabeled with iodine-131

Trial Locations (8)

Rigshospitalet, Copenhagen

Memorial Sloan Kettering Cancer Center, New York

Nationwide Children's Hospital, Columbus

Riley Hospital for Children, Indianapolis

M.D. Anderson Cancer Center, Houston

Childrens Hospital Los Angeles, Los Angeles

Department of Pediatric Oncology Fukushima Medical University Hospita, Fukushima

Hospital Sant Joan de Déu, Barcelona